Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Shouldn’t pharmacovigilance be less painful?
Posted on May 26th, 2017 by Betsy Davis in Pharmacovigilance
Even with advanced information technologies, too many companies and pharmacovigilance practitioners are still living with the pain of having to rely on ineffective and outdated systems and processes.
In particular, the right literature monitoring solutions can help companies keep on top of the millions of ADRs reported yearly worldwide. Purpose-built technology can play a key role in more proactively identifying ADRs, supporting audit readiness, having comprehensive access and insights across key data sources, and more.
Still, the opportunity in literature monitoring solutions can only be fully leveraged if one considers the fuller picture of how their organization’s end-to-end PV process works.
To illustrate, we’ve prepared this short video below:
The full whitepaper can be found here. It outlines some practical steps that pharmacovigilance teams can take to plan, implement and maintain better global oversight of their PV processes. Given how regulatory changes are expanding the scope and complexity of pharmacovigilance, and the ever-increasing amount of information to be monitored for safety signals, I hope this whitepaper provides food for thought.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Senior Strategic Marketing Manager
- Can We Apply Leadership Skills to Writing Pharmacovigilance SOPs?
- What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?
- Building a balanced search formula for pharmacovigilance and literature monitoring
- Building PV SOPs: Where to start?
- Easing the Pain in Monitoring Literature for Adverse Drug Events